The present invention relates to IL-4 antagonists that include, but arenot limited to, IL-4 receptors (such as a soluble human IL-4 receptor),antibodies thatbind IL-4, antibodies that bind IL-4R, IL-4 muteins that bind to IL-4R but donot inducea biological response, molecules that inhibit IL-4-induced signaltransduction, andother compounds that inhibit a biological effect that results from the bindingof IL-4 toa cell surface IL-4R. Particular antibodies provided herein include humanmonoclonalantibodies generated by procedures involving immunization of transgenic mice.Such human antibodies may be raised against human IL-4 receptor. Certain oftheantibodies inhibit both IL-4-induced and IL-13-induced biological activities.
